• Biotechnology company BiondVax has entered into a collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”) to develop innovative NanoAbs
• BiondVax enjoys an exclusive option for an exclusive worldwide license agreement at pre-agreed financial terms for additional NanoAbs discovered and characterized thereunder the RCA
• The company recently announced intent to develop innovative NanoAbs targeting immune system cytokines such as IL-17 for the potential treatment of psoriasis and psoriatic arthritis
• Analysts at Zacks Small-Cap Research laud the shift in focus to anti-IL-17 and have pegged the stock to reach $8 per share from current levels of below $2 per share

Last September, a joint steering committee comprising professionals from BiondVax Pharmaceuticals (NASDAQ: BVXV), the Max Planck Institute for Multidisciplinary Sciences (“MPG”), and the University Medical Center Göttingen (“UMG”), made a decision. Established to guide the BVXV-MPG-UMG NanoAb collaboration, the committee decided to focus the nanosized antibody (“NanoAb”) development on other therapeutic indications in addition to COVID-19. This renewed focus would begin with the development of NanoAbs targeting immune system cytokines such as IL-17 (IL-17A, IL-17F, and IL-17A/F) for the potential treatment of psoriasis and psoriatic arthritis and IL-13 for the potential treatment of asthma (https://ibn.fm/AFw7N).

The committee’s decision is anchored in a five-year definitive research collaboration agreement (“RCA”) entered between BVXV, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, and its collaborators, MPG and UMG, allowing…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.